Bio-Reference Laboratories, Inc. Again Awarded New York State Department of Corrections Laboratory Services Contract
More News related to BRLI
- Bio-Reference Laboratories, Inc. Again Awarded New York State Department of Corrections Laboratory Services Contract
- SmallCapSentinel.com: Records and Revenues
- BioReference Laboratories, Inc to Speak at the Oppenheimer 20th Annual Health Care Conference
- Bio-Reference Laboratories (BRLI) Tops The Q3 View By 8c
- Jefferies & Co Downgrades Bio-Reference Labs (BRLI) to Hold
More News related to Press Releases
- Wunderlich Securities Downgrades Gran Tierra Energy (GTE) to Hold
- Stephens Downgrades Benihana (BNHN) to Equalweight
- UBS Downgrades NRG Energy (NRG) to Neutral; Cuts Target to $26
- Citi Cuts Lukoil (LUKOY) to Hold
- RBC Upgrades Diamond Rock (DRH) to Outperform, Downgrades Hospitality Properties (HPT) to Sector Perform
Continuation of contract that was first initiated in 1998 remains with BioReference
ELMWOOD PARK, N.J.--(BUSINESS WIRE)-- Bio-Reference Laboratories, Inc. (NASDAQ: BRLI) announced today that the State of New York Department of Correctional Services has once again selected BRLI to be the Department's provider of Statewide Laboratory Services. Pursuant to its internal requirements, the Department submits its contract for laboratory services for bid and proposal every five (5) years. The State first went to a unified statewide contract for laboratory services in 1998 and since that time BRLI has continuously been the provider of laboratory services. Over the next five years, BRLI indicated that it expects revenues from this Contract to exceed $35M.
About BioReference Laboratories, Inc.
BRLI is the third largest full service laboratory in the United States and the largest independent regional laboratory in the Northeastern market, primarily a clinical testing lab servicing physician offices with concentrations in the focused markets of esoteric testing, molecular diagnostics, anatomical pathology and correctional health care. BRLI operates as a national oncology laboratory under its GenPath label. Better science, superior technology and better service have enabled GenPath to earn a reputation as one of the premier hematopathology laboratories in the country. BRLI's innovative technology platform for sexually transmitted infections has enabled it to expand as a national laboratory in the area of Women's Health. GeneDx, a wholly owned subsidiary, is the BRLI genetics laboratory and is typically recognized as the leading laboratory for testing of rare genetic diseases; GeneDx has now become a technology leader with GenomeDx, based on a CGH array platform and its NextGen sequence offerings that are currently offered in cardiology and will be offered in the future in other disease specific areas.
Statements included in this release that are not historical in nature, are intended to be, and are hereby identified as "forward-looking statements". Statements looking forward in time are included in this release pursuant to the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. Such statements involve known and unknown risks and uncertainties that may cause the Company's actual results in future periods to be materially different from any future performance suggested herein.
Source: Bio-Reference Laboratories, Inc.
Related Categories
Press ReleasesStocks Mentioned
-0.40Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
